- Home
- NAT vs ABUS Comparison
NAT vs ABUS Comparison
Compare NAT & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAT
- ABUS
- Stock Information
- Founded
- NAT 1995
- ABUS 2005
- Country
- NAT Bermuda
- ABUS United States
- Employees
- NAT N/A
- ABUS N/A
- Industry
- NAT Marine Transportation
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- NAT Consumer Discretionary
- ABUS Health Care
- Exchange
- NAT Nasdaq
- ABUS Nasdaq
- Market Cap
- NAT 582.3M
- ABUS 685.7M
- IPO Year
- NAT 1997
- ABUS N/A
- Fundamental
- Price
- NAT $2.64
- ABUS $3.09
- Analyst Decision
- NAT Hold
- ABUS Strong Buy
- Analyst Count
- NAT 2
- ABUS 4
- Target Price
- NAT $3.50
- ABUS $5.50
- AVG Volume (30 Days)
- NAT 3.0M
- ABUS 793.1K
- Earning Date
- NAT 07-11-2025
- ABUS 07-31-2025
- Dividend Yield
- NAT 12.93%
- ABUS N/A
- EPS Growth
- NAT N/A
- ABUS N/A
- EPS
- NAT 0.17
- ABUS N/A
- Revenue
- NAT $327,115,000.00
- ABUS $6,403,000.00
- Revenue This Year
- NAT N/A
- ABUS $3.35
- Revenue Next Year
- NAT $6.07
- ABUS N/A
- P/E Ratio
- NAT $16.08
- ABUS N/A
- Revenue Growth
- NAT N/A
- ABUS N/A
- 52 Week Low
- NAT $2.13
- ABUS $2.71
- 52 Week High
- NAT $4.01
- ABUS $4.73
- Technical
- Relative Strength Index (RSI)
- NAT 50.59
- ABUS 37.60
- Support Level
- NAT $2.62
- ABUS $3.29
- Resistance Level
- NAT $2.87
- ABUS $3.65
- Average True Range (ATR)
- NAT 0.09
- ABUS 0.13
- MACD
- NAT -0.01
- ABUS -0.03
- Stochastic Oscillator
- NAT 38.89
- ABUS 14.29
About NAT Nordic American Tankers Limited
Nordic American Tankers Ltd owns and operates double-hull crude oil tankers. It is an international tanker company that owns double-hull Suezmax tankers. It operates vessels in the spot market or on spot market-related charters according to cooperative arrangements with third parties. The company's fleet consists of crude oil tankers, and all of its vessels are employed in the spot market. The company has only one type of vessel - Suezmax crude oil tankers. It operates in markets that are very competitive and based mainly on supply and demand.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.